Received: 2 August 2022
Accepted: 6 December 2022
First Online: 24 December 2022
: This project was registered as a service evaluation (reference number: CSS094) on 19th April 2022 with the Chelsea & Westminster NHS Foundation Trust Clinical Governance Committee. Additional ethical review was not required for this study as per the Committee. The need for individual patient written informed consent was waived for this retrospective cohort study by the Chelsea & Westminster NHS Foundation Trust Clinical Governance Committee. All data collected was stored in concordance with Data Protection Act 2018 and General Data Protection Regulation. All procedures were performed in accordance with relevant guidelines.
: No data necessitating consent was used in this study.
: LSPM has consulted for/received speaker fees from bioMerieux (2013–2022), Eumedica (2016–22) DNAelectronics (2015–2018), Dairy Crest (2017–2018), Profile Pharma (2018), Umovis Labs (2020–2021), Kent Pharma (2021), Shionogi (2021–2022), Pulmocide (2021), Sumitovant (2021–2022), and Pfizer (2018–2022), and received research grants from the National Institute for Health Research (2013–2022), Leo Pharma (2016), LifeArc (2020–2022), and CW + Charity (2018–2022). NM has consulted for Pfizer (2019–2022) and received educational support from Eumedica (2015) and Baxter (2017). SH has consulted for/received speaker fees Shionogi (2021–22), BowMed (2021), Eumedica (2020), Kent Pharma (2021), Gilead (2021–22), Tillots (2022), Baxter (2022) and Pfizer (2020–2022) and received research grants from the CW + Charity (2021–2022). All other authors have no conflicts of interest to declare<b>.</b>